Psagot Investment House Ltd. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 37.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 200,651 shares of the biopharmaceutical company’s stock after selling 118,447 shares during the quarter. Psagot Investment House Ltd.’s holdings in Gilead Sciences were worth $15,492,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. boosted its position in Gilead Sciences by 5.3% during the first quarter. Principal Financial Group Inc. now owns 2,945,595 shares of the biopharmaceutical company’s stock worth $222,068,000 after acquiring an additional 148,398 shares during the last quarter. Fisher Asset Management LLC boosted its position in Gilead Sciences by 5.9% during the second quarter. Fisher Asset Management LLC now owns 559,568 shares of the biopharmaceutical company’s stock worth $39,640,000 after acquiring an additional 31,109 shares during the last quarter. Xact Kapitalforvaltning AB boosted its position in Gilead Sciences by 1.2% during the second quarter. Xact Kapitalforvaltning AB now owns 264,883 shares of the biopharmaceutical company’s stock worth $18,764,000 after acquiring an additional 3,057 shares during the last quarter. Addenda Capital Inc. boosted its position in Gilead Sciences by 91.5% during the second quarter. Addenda Capital Inc. now owns 155,142 shares of the biopharmaceutical company’s stock worth $11,357,000 after acquiring an additional 74,123 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. boosted its position in Gilead Sciences by 2.0% during the second quarter. NN Investment Partners Holdings N.V. now owns 942,209 shares of the biopharmaceutical company’s stock worth $66,748,000 after acquiring an additional 18,385 shares during the last quarter. Institutional investors own 78.09% of the company’s stock.
A number of research firms recently weighed in on GILD. ValuEngine lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, August 20th. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, July 31st. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 18th. Zacks Investment Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, Cantor Fitzgerald boosted their target price on shares of Gilead Sciences from $87.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, October 26th. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $87.84.
In other news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $78.04, for a total value of $3,902,000.00. Following the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $239,408,146.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 150,000 shares of company stock worth $11,087,500 over the last three months. Insiders own 1.30% of the company’s stock.
Gilead Sciences stock opened at $71.18 on Friday. The company has a market capitalization of $93.76 billion, a PE ratio of 11.29, a P/E/G ratio of -2.81 and a beta of 1.01. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period in the previous year, the firm earned $2.27 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 6.44 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/11/10/gilead-sciences-inc-gild-shares-sold-by-psagot-investment-house-ltd.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.